omniture
logo
Search
德琪（浙江）医药科技有限公司 Deqi (zhejiang) Pharmaceutical Technology Co. LTD
Media Room

Latest News

rss

Antengene Submits NDA for ATG-010 (Selinexor) in South Korea for rrMM and rrDLBCL

SHANGHAI and HONG KONG, Jan. 4, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2021-01-04 08:00 4558

Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy

SHANGHAI and HONG KONG, Dec. 21, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2020-12-21 08:00 4193

Antengene Announces Approval of IND Application in China for a Phase 3 Clinical Trial of ATG-010 (Selinexor) in Combination with Bortezomib and Dexamethasone (SVd) for the Treatment of rrMM

SHANGHAI and HONG KONG, Dec.18, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2020-12-18 15:34 5845

Antengene Announces Acceptance of IND Application in China for a Phase 3 Clinical Trial of ATG-010 (Selinexor) in Combination with Bortezomib and Dexamethasone (SVd) for the Treatment of rrMM

SHANGHAI and HONG KONG, Dec. 11, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", S...

2020-12-11 08:00 5329

Antengene Announces Collaboration with Applied BioMath, LLC for Systems Pharmacology Modeling in Oncology

SHANGHAI and HONG KONG, Dec. 9, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SE...

2020-12-09 08:00 3892

Antengene Announces Acceptance of IND Application in China for ATG-010 (selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study

SHANGHAI and HONG KONG, Dec. 7, 2020 /PRNewswire/ --  Antengene Corporation Limited ("Antengene", ...

2020-12-07 08:00 3970
1 ... 56789